Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
BioDrugs
Erschienen in: BioDrugs 1/2013

01.02.2013 | Adis Drug Clinical Q&A

Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)

A Guide to Its Use as a Single-Dose Booster Immunization Against Pertussis

verfasst von: Lesley J. Scott, Paul L. McCormack

Erschienen in: BioDrugs | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus, and pertussis. In clinical trials, a single booster dose of Tdap induced high seroprotective levels of antibodies to its three component acellular pertussis antigens in virtually all children and adolescents, and in a high proportion of adults and elderly individuals, at ≈1 month post-vaccination, irrespective of their vaccination history. Seropositivity rates for antibodies against pertussis toxin had begun to decline by 5 years after a booster dose of Tdap in adolescents/adults, with a subsequent booster dose 10 years later generally as immunogenic and as well tolerated as the initial booster. Tdap was safe and well tolerated in all age groups.
Literatur
1.
Di Pasquale A, Wolter J, Schuerman L. Management of pertussis in adolescents and adults: the role of a reduced-antigen content combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine. J Prev Med Hyg. 2005;46(1):33–41.
2.
Halperin SA, Scheifele D, De Serres G, et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine. 2012;30(5):974–82.PubMedCrossRef
3.
World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(40):385–400.
4.
McCormack PL. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its use as a single-dose booster immunization. Drugs. 2012;72(13):1765–91.PubMedCrossRef
5.
Center for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with infants aged <12 months: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60(11):1424–6.
6.
7.
Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed): US prescribing information. Research Triangle Park (SC): GlaxoSmithKline;2012.
8.
Boostrix suspension for injection (diphtheria, tetanus and pertussis [acellular, component] vaccine [adsorbed, reduced antigen(s) content]): summary of product characteristics. London: European Medicines Agency;2012.
9.
Zhu F, Zhang S, Hou Q, et al. Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix™). Hum Vaccin. 2010;6(3):263–9.CrossRef
10.
Huang LM, Chang LY, Tang H, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. J Adolesc Health. 2005;37(6):517.e1–5.CrossRef
11.
Kosuwon P, Warachit B, Hutagalung Y, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine. 2003;21(27–30):4194–200.PubMedCrossRef
12.
Zepp F, Cheuvart B, Wolter JM. Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (DTPA) in pre-school-aged children [abstract no. 281.00 plus poster]. In: 21st Annual Meeting of the European Society for Paediatric Infectious Diseases, 9–11 Apr 2003, Taormina, Italy.
13.
Pichichero ME, Blatter MM, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084–93.PubMedCrossRef
14.
Theeten H, Van Damme P, Hoppenbrouwers K, et al. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine. 2005;23(12):1515–21.PubMedCrossRef
15.
Abarca K, Valdivieso F, Potin M, et al. Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine (dTpa) in 10 to 11 years old children and in adults [in Spanish]. Rev Med Chil. 2002;130(5):502–10.PubMed
16.
Knuf M, Zepp F, Meyer C, et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine. 2006;24(12):2043–8.PubMedCrossRef
17.
Southern J, Andrews N, Burrage M, et al. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine. 2005;23(29):3829–35.PubMedCrossRef
18.
Tran Minh NN, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics. 1999; 104(6):e70.
19.
Booy R, Van Der Meeren O, Ng SP, et al. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine. 2010;29(1):45–50.PubMedCrossRef
20.
Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis. 2010;51(6):656–62.PubMedCrossRef
21.
Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19–64 years of age. Vaccine. 2009;27(5):765–72.PubMedCrossRef
22.
Chan SH, Tan PTN, Han HH, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults. Singap Med J. 2006;47(4):286–90.
23.
Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine. 2000;19(6):628–36.PubMedCrossRef
24.
Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000;18(20):2075–82.PubMedCrossRef
25.
Weston WM, Friedland LR, Wu X, et al. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): results of two randomized trials. Vaccine. 2012;30(9):1721–8.PubMedCrossRef
26.
Schmitt HJ, von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275(1):37–41.PubMedCrossRef
27.
Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr. 1996;129(5):695–701.PubMedCrossRef
28.
Weston W, Messier M, Friedland LR, et al. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine. Vaccine. 2011;29(47):8483–6.PubMedCrossRef
29.
McIntyre PB, Turnbull FM, Egan AM, et al. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine. 2004;23(3):380–5.PubMedCrossRef
30.
Edelman K, He Q, Makinen J, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis. 2007;44(10):1271–7.PubMedCrossRef
31.
Edelman KJ, He Q, Makinen JP, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis. 2004;39(2):179–85.PubMedCrossRef
32.
Evaluation of GSK Biologicals’ Boostrix™ in healthy adults, 10 years after previous booster vaccination (result summary of study no. 113055). Brentford, UK: GlaxoSmithKline; 2011.
33.
McIntyre PB, Burgess MA, Egan A. Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine. 2009;27(7):1062–6.PubMedCrossRef
34.
Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Ped Infect Dis J. 2009;28(2):152–3.CrossRef
35.
Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555–63.PubMedCrossRef
36.
Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis. 2010;51(3):315–21.PubMedCrossRef
37.
Zepp F, Knuf M, Habermehl P, et al. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr. 2006;149(5):603–10.PubMedCrossRef
38.
Bose A, Dubey AP, Gandhi D, et al. Safety and reactogenicity of a low-dose diphtheria-tetanus-acellular pertussis vaccine (Boostrix™) in pre-school Indian children. Indian Pediatr. 2007;44(6):421–4.PubMed
39.
Vergara R, Tregnaghi M, Ussher J, et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr. 2005;164(6):377–82.PubMedCrossRef
40.
Weston WM, Friedland LR, Wu X. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011;29(5):1017–22.PubMedCrossRef
41.
Weston WM, Chandrashekar V, Friedland LR, et al. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccin. 2009;5(12):858–66.PubMed
42.
Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J. 2011;30(12):e225–34.PubMedCrossRef
43.
Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States Health Maintenance Organization. Pediatr Infect Dis J. 2010;29(7):613–7.PubMedCrossRef
44.
Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine. 2009;27(32):4257–62.PubMedCrossRef
Metadaten
Titel
Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)
A Guide to Its Use as a Single-Dose Booster Immunization Against Pertussis
verfasst von
Lesley J. Scott
Paul L. McCormack
Publikationsdatum
01.02.2013
Verlag
Springer International Publishing AG
Erschienen in
BioDrugs / Ausgabe 1/2013
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-012-0009-y

Weitere Artikel der Ausgabe 1/2013

BioDrugs 1/2013 Zur Ausgabe

Adis Drug Clinical Q&A

Vincristine Sulfate Liposome Injection

Original Research Article

Selection of Potential Therapeutic Human Single-Chain Fv Antibodies against Cholecystokinin-B/Gastrin Receptor by Phage Display Technology

Review Article

A New Strategy for Treatment of Liver Fibrosis

Review Article

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer

Leading Article

Targeting Focal Adhesion Kinase in Fibrotic Diseases

Leading Article

Targeting the B7 Family of Co-Stimulatory Molecules